BACKGROUND: Computed tomography (CT) lung cancer screening offers a unique clinical setting in which to promote smoking cessation. Focusing on outcomes related to the reporting of CT abnormality, we examined the natural history of smoking in the Pittsburgh Lung Screening Study. METHODS: Pittsburgh Lung Screening Study recruited 50- to 79-year-old current and former cigarette smokers living in the Pittsburgh area. We examined self-reported smoking outcomes 1 year after study entry in a subgroup that contained 2,094 active cigarette smokers without interval lung cancer diagnosis (50.7% women; median age, 57 years; 40-year median duration of cigarette smoking; and 65.2% > or =20 cigarettes/d). Analyses compared efforts to quit in relation to physician referral for abnormal CT. RESULTS: Since study entry, 58.5% [95% confidence interval (95% CI), 56.3-60.6%] reported any quit attempt and 27.2% (95% CI, 25.3-29.1%) reported any quit interval >30 days. One year after study entry, 15.5% (95% CI, 14.0-17.1%) reported not smoking for >30 days. Comparing persons referred because of CT abnormalities creating moderate or high lung cancer suspicion (n = 156; 7.4%) to persons not referred for any reason (n = 1145; 54.7%), propensity score-adjusted fractions with any quit attempt and with any quit interval >30 days increased 18.8% (95% CI, 11.1-26.5%) and 17.7% (95% CI, 9.4-26.0%), respectively. The fraction quit >30 days at 1 year increased 12.2% (95% CI, 4.9-19.5%). CONCLUSIONS: Persons who experienced referral because of abnormal CT reported more smoking cessation.
BACKGROUND: Computed tomography (CT) lung cancer screening offers a unique clinical setting in which to promote smoking cessation. Focusing on outcomes related to the reporting of CT abnormality, we examined the natural history of smoking in the Pittsburgh Lung Screening Study. METHODS: Pittsburgh Lung Screening Study recruited 50- to 79-year-old current and former cigarette smokers living in the Pittsburgh area. We examined self-reported smoking outcomes 1 year after study entry in a subgroup that contained 2,094 active cigarette smokers without interval lung cancer diagnosis (50.7% women; median age, 57 years; 40-year median duration of cigarette smoking; and 65.2% > or =20 cigarettes/d). Analyses compared efforts to quit in relation to physician referral for abnormal CT. RESULTS: Since study entry, 58.5% [95% confidence interval (95% CI), 56.3-60.6%] reported any quit attempt and 27.2% (95% CI, 25.3-29.1%) reported any quit interval >30 days. One year after study entry, 15.5% (95% CI, 14.0-17.1%) reported not smoking for >30 days. Comparing persons referred because of CT abnormalities creating moderate or high lung cancer suspicion (n = 156; 7.4%) to persons not referred for any reason (n = 1145; 54.7%), propensity score-adjusted fractions with any quit attempt and with any quit interval >30 days increased 18.8% (95% CI, 11.1-26.5%) and 17.7% (95% CI, 9.4-26.0%), respectively. The fraction quit >30 days at 1 year increased 12.2% (95% CI, 4.9-19.5%). CONCLUSIONS:Persons who experienced referral because of abnormal CT reported more smoking cessation.
Authors: Kavita Garg; Robert L Keith; Tim Byers; Karen Kelly; Anne L Kerzner; David A Lynch; York E Miller Journal: Radiology Date: 2002-11 Impact factor: 11.105
Authors: David O Wilson; Joel L Weissfeld; Carl R Fuhrman; Stephen N Fisher; Paula Balogh; Rodney J Landreneau; James D Luketich; Jill M Siegfried Journal: Am J Respir Crit Care Med Date: 2008-07-17 Impact factor: 21.405
Authors: M Bade; V Bähr; U Brandt; A Eigentopf; T Brüchert; M-L Gross; E Motsch; N Becker Journal: J Cancer Res Clin Oncol Date: 2016-01-27 Impact factor: 4.553
Authors: Lisa M Fucito; Sharon Czabafy; Peter S Hendricks; Chris Kotsen; Donna Richardson; Benjamin A Toll Journal: Cancer Date: 2016-02-24 Impact factor: 6.860
Authors: Alana M Rojewski; Nichole T Tanner; Lin Dai; James G Ravenel; Mulugeta Gebregziabher; Gerard A Silvestri; Benjamin A Toll Journal: Chest Date: 2018-05-21 Impact factor: 9.410
Authors: Samantha A Barry; Martin C Tammemagi; Sofiya Penek; Elisabeth C Kassan; Caroline S Dorfman; Thomas L Riley; John Commin; Kathryn L Taylor Journal: J Natl Cancer Inst Date: 2012-10-26 Impact factor: 13.506
Authors: Martin C Tammemägi; Christine D Berg; Thomas L Riley; Christopher R Cunningham; Kathryn L Taylor Journal: J Natl Cancer Inst Date: 2014-05-28 Impact factor: 13.506
Authors: Shuguang Leng; Joel L Weissfeld; Maria A Picchi; Mindi A Styn; Eric D Claus; Vincent P Clark; Guodong Wu; Cynthia L Thomas; Frank D Gilliland; Jianmin Yuan; Jill M Siegfried; Steven A Belinsky Journal: Int J Mol Epidemiol Genet Date: 2016-06-01
Authors: Richard Wender; Elizabeth T H Fontham; Ermilo Barrera; Graham A Colditz; Timothy R Church; David S Ettinger; Ruth Etzioni; Christopher R Flowers; G Scott Gazelle; Douglas K Kelsey; Samuel J LaMonte; James S Michaelson; Kevin C Oeffinger; Ya-Chen Tina Shih; Daniel C Sullivan; William Travis; Louise Walter; Andrew M D Wolf; Otis W Brawley; Robert A Smith Journal: CA Cancer J Clin Date: 2013-01-11 Impact factor: 508.702